{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Grade 2 Treatment Related Toxicities"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Grade 3/4 Treatment Related Toxicities"}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"The toxicity and safety of systemic infusion of anti-TGF antibody at three-week dosing intervals. Number subjects with Grade 2 and Grade 3/4 treatment related toxicities.","groups":[{"description":"Phase II, Single-Arm, Multi-Site study. All subjects will receive the investigational agent, GC1008 in 3 week cycles of treatment\n\nGC1008: GC1008 is a human IgG4 kappa monoclonal antibody capable of neutralizing all mammalian isoforms of TGFbeta (i.e., beta1, beta 2 and beta 3). GC1008 is a high affinity antibody with dissociation constants (Kds) of 1.8 nM, 2.8 nM and 1.4 nM for TGF1,2,and 3, respectively.","id":"OG000","title":"Investigational Drug infusion-for Safety and Effectiveness"}],"paramType":"NUMBER","populationDescription":"Outcome analysis presented in manuscript of results of trial based on 13 participants.","reportingStatus":"POSTED","timeFrame":"18 months","title":"Toxicity and Safety of Systemic Infusion of Anti-TGF Antibody","type":"SECONDARY","unitOfMeasure":"participants"}